Status:

COMPLETED

Benefit/Risk Evaluation of Insuman Implantable Versus Insuplant Using Medtronic MiniMed Implantable Pump System in Patients With Type 1 Diabetes

Lead Sponsor:

Sanofi

Conditions:

Diabetes Mellitus, Type 1

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

Primary Objective: To compare Insuman Implantable 400 IU/ml versus Insuplant 400 IU/ml with respect to the pump refill accuracy during a 4 refill cycle period (i.e. the comparative phase); To assess ...

Detailed Description

The study duration will be displayed in 2 parts as follow: Comparative phase (only French patients): 160 +/- 20 days Open label Insuman Implantable extension phase (French and European patients): fro...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Patients already treated with Insuplant 400 IU/ml via a Medtronic Implantable System 2007
  • Glycosylated hemoglobin ≤9.0%
  • Patient showing a percentage of error at refill equal or below 20%
  • Patient undergoing NaOH rinse procedure of at least 10 minutes period with or without flush Or Patient being re-implanted with a new pump (first fill with insulin)
  • Signed informed consent form prior to enrolment
  • Exclusion criteria:
  • Pump life time \> 6 years
  • Pump battery voltage \< 2.6 volts
  • Pregnancy or childbearing potential without a medically approved form of birth control
  • The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Exclusion

    Key Trial Info

    Start Date :

    November 16 2010

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    February 1 2018

    Estimated Enrollment :

    479 Patients enrolled

    Trial Details

    Trial ID

    NCT01194882

    Start Date

    November 16 2010

    End Date

    February 1 2018

    Last Update

    February 15 2018

    Active Locations (17)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 5 (17 locations)

    1

    Investigational Site Number 056-001

    Leuven, Belgium, 3000

    2

    Investigational Site Number 250-004

    Corbeil-Essonnes, France, 91100

    3

    Investigational Site Number 250-008

    Dijon, France, 21000

    4

    Investigational Site Number 250-003

    Dommartin-lès-Toul, France, 54200

    Benefit/Risk Evaluation of Insuman Implantable Versus Insuplant Using Medtronic MiniMed Implantable Pump System in Patients With Type 1 Diabetes | DecenTrialz